1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
2018;68(6):394–424. doi: 10.3322/caac.21492.
2. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. Jama.
1990;264(11):1444–1450.
3. Grothey A, Sobrero AF, Shields AF, et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
N Engl J Med. 2018;378(13):1177–1188. doi:10.1056/NEJMoa1713709.
4. McCleary NJ, Meyerhardt JA, Green E, et al. Impact of age on the efficacy of newer adjuvant
therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol.
2013;31(20):2600–2606. doi:10.1200/JCO.2013.49.6638.
5. Haller DG, O’Connell MJ, Cartwright TH, et al. Impact of age and medical comorbidity on adjuvant
treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four
randomized, controlled trials. Ann Oncol. 2015;26(4):715–724. doi:10.1093/annonc/mdv003.
6. Dotan E, Browner I, Hurria A, Denlinger C. Challenges in the management of older patients with colon
cancer. J Natl Compr Canc Netw. 2012;10(2):213–224; quiz 225.
7. McCleary NJ, Dotan E, Browner I. Refining the chemotherapy approach for older patients with colon
cancer. J Clin Oncol. 2014;32(24):2570–2580. doi:10.1200/JCO.2014.55.1960.
8. Muss HB, Bynum DL. Adjuvant chemotherapy in older patients with stage III colon cancer: an underused
lifesaving treatment. J Clin Oncol. 2012;30(21):2576–2578. doi:10.1200/JCO.2012.42.3780.
9. Sanoff HK, Carpenter WR, Sturmer T, et al. Effect of adjuvant chemotherapy on survival of patients with
stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012;30(21):2624–2634. doi:10.1200/
JCO.2011.41.1140.
10. Hanna NN, Onukwugha E, Choti MA, et al. Comparative analysis of various prognostic nodal factors,
adjuvant chemotherapy and survival among stage III colon cancer patients over 65 years: an analysis using
surveillance, epidemiology and end results (SEER)-Medicare data. Colorectal disease. 2012;14(1):48–55.
doi:10.1111/j.1463-1318.2011.02545.x.
11. Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR)
guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23(1):1–34. doi:10.1007/
s10147-017-1101-6.
12. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow
Transplant. 2013;48(3):452–458. doi: 10.1038/bmt.2012.244.
13. Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated
611
Oxaliplatin for elderly patients
14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(3):3768–3774.
doi:10.1200/JCO.2011.36.4539.
Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin
as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–
3116. doi:10.1200/JCO.2008.20.6771.
Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic
acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–1471. doi:10.1200/
JCO.2010.33.6297.
Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and
leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
J Clin Oncol. 2007;25(16):2198–2204. doi:10.1200/JCO.2006.08.2974.
Shimada Y, Hamaguchi T, Mizusawa J, et al. Randomised phase III trial of adjuvant chemotherapy with oral
uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III
colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
Eur J Cancer. 2014;50(13):2231–2240. doi:10.1016/j.ejca.2014.05.025.
Benson AB, 3rd, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Colon Cancer, Version
2.2018. J Natl Compr Canc Netw. 2018;16(4):359–369. doi: 10.6004/jnccn.2018.0021.
Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the
Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer. 2012;118(13):3377–
3386. doi:10.1002/cncr.26646.
Hurria A, Mohile S, Gajra A, et al. Validation of a Prediction Tool for Chemotherapy Toxicity in Older
Adults With Cancer. J Clin Oncol. 2016;34(20):2366–2371. doi:10.1200/JCO.2015.65.4327.
Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a
prospective multicenter study. J Clin Oncol. 2011;29(25):3457–3465. doi:10.1200/JCO.2011.34.7625.
Hayashi N, Matsuoka A, Goto H, et al. Clinical effectiveness of geriatric assessment for predicting the
tolerability of outpatient chemotherapy in older adults with cancer. J Geriatr Oncol. 2018;9(1):84–86.
doi:10.1016/j.jgo.2017.07.014.
VanderWalde N, Jagsi R, Dotan E, et al. NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016.
J Natl Compr Canc Netw. 2016;14(11):1357–1370.
Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer
patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology
(SIOG). Crit Rev Oncol Hematol. 2005;55(3):241–252. doi:10.1016/j.critrevonc.2005.06.003.
...
論文の公開元へ
